Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT03460379
Recruiting Observational

Bariatric Surgery and Pharmacokinetics of Escitalopram

NCT03460379 · tracked via the Priya Life Science Norway tracker
Sponsor
Norwegian University of Science and Technology
Phase
Observational
Started
2016-11-02
Last updated
2023-03-27

Condition(s) studied

Obesity, Morbid

Investigational drug(s) / intervention(s)

Escitalopram →

Escitalopram: Patients are tested for their normal prescription escitalopram medication

Study summary

Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on escitalopram are investigated.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
St. Olavs University Hospital Trondheim Norway Recruiting

On this site

📄 Lexapro (escitalopram) drug profile →

More Norwegian University of Science and Technology trials in Norway

MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway Active, not recruiting
Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae Active, not recruiting
Multimodal Assesment of Alzheimer Patients Recruiting
Bariatric Surgery and Pharmacokinetics of Quetiapine Recruiting
Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes Starting soon

Other trials for the same condition

Bariatric Surgery and Pharmacokinetics of Quetiapine Recruiting
Bariatric Surgery and Pharmacokinetics of Apixaban Recruiting
Bariatric Surgery and Pharmacokinetics of Fluoxetine Recruiting
Bariatric Surgery and Pharmacokinetics of Ramipril Recruiting
Non-randomized Prospective Comparison Between SASI Bipartition and RYGB Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03460379 on ClinicalTrials.gov ↗ ← All trials in Norway